Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

Keytruda (pembrolizumab) has been approved for use in combination with chemoradiotherapy (CRT) for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to ...

A life-extending drug for advanced cervical cancer will be made available to NHS patients in England, like it is in Scotland, new recommendations say. Pembrolizumab can mean extra months of life ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat ...

Cervical cancer is the fourth most common cancer in women globally ... "For some people whose cancer has markers for the protein PD-L1, we're able to use pembrolizumab — an immunotherapy drug called ...

A new report from leading contract research organisation Novotech has shed light on the current state of play in the global ...

Merck’s Keytruda receives European approval for two new indications in gynaecologic cancers: Rahway, New Jersey Friday, October 25, 2024, 09:00 Hrs [IST] Merck, known as MSD out ...

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

Our research helped get the drugs pembrolizumab and nivolumab approved for treating head and neck cancers – a smarter, kinder alternative to chemotherapy. We are also developing therapies that improve ...

The NCCN 2024 guidelines include recommendations such as chemoradiation and pembrolizumab-based therapies for PD-L1-positive tumors. Treatment options for recurrent or metastatic cervical cancer ...

and PFS compared to concurrent CRT alone for newly diagnosed patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer. In June 2024, KEYTRUDA in combination with carboplatin and ...